08/02/2026
Delighted to share the landmark launch of ORSEMA(Semaglutide PFS) in Upper Myanmar (Mandalay)—a scientifically enriching and strategically significant event attended by more than 200 leading doctors and medical professionals.
The tremendous engagement reflected the growing clinical and academic interest in Semaglutide across Myanmar and the clear shift towards evidence‑based, protocol‑driven cardio‑metabolic care. The depth of discussion reinforced the urgent need for structured, research‑focused medical education that equips clinicians with the latest global evidence and real‑world insights.
As emerging data continues to broaden Semaglutide’s therapeutic scope—well beyond glycaemic control and weight reduction—the role of scientific dialogue, continuous medical education, and multidisciplinary collaboration becomes ever more essential. Orsema is proudly positioned to contribute meaningfully to improved patient outcomes across metabolic and cardiometabolic conditions.
Sincere appreciation goes to our distinguished academic panel:
• Prof. Aye Aye Chit (Chairperson)
• Prof. Kyaw Soe Win (Speaker )
• Prof. San San Win(Speaker )
Thank you to all healthcare professionals who engaged, questioned, and shared valuable perspectives—your commitment to advancing patient care drives real progress.
A special commendation to our valued partner ABC Intl. for delivering such a grand and successful scientific event.
Together, let’s continue championing scientific advancement, elevating clinical practice, and shaping a healthier future for patients across Myanmar.
